5-year follow-up of a RCT in unresectable pleural mesothelioma: first-line nivolumab plus ipilimumab vs chemotherapy kept an overall survival benefit (5-year OS 14% vs 6%; HR 0.74), and after adjusting for treatment switching (HR 0.64). No new safety signals.
RCT
Scherpereel et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743